Sinecatechins
Veregen (sinecatechins) is an unknown pharmaceutical. Sinecatechins was first approved as Veregen on 2006-10-31.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Veregen
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sinecatechins
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VEREGEN | ANI PHARMS | N-021902 RX | 2006-10-31 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| veregen | New Drug Application | 2022-11-10 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
500 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anesthesia | D000758 | 3 | 5 | 10 | 19 | 29 | 64 | ||
| General anesthesia | D000768 | 1 | 2 | 5 | 8 | 12 | 27 | ||
| Postoperative pain | D010149 | G89.18 | 1 | 1 | 1 | 6 | 12 | 21 | |
| Emergence delirium | D000071257 | — | — | — | 6 | 9 | 15 | ||
| Delirium | D003693 | R41.0 | 1 | 1 | — | 6 | 6 | 14 | |
| Postoperative cognitive complications | D000079690 | 2 | 1 | — | 2 | 6 | 10 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | 3 | 5 | 9 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | — | 4 | 3 | 7 | |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | 4 | 2 | 1 | 7 |
| Hypotension | D007022 | EFO_0005251 | I95 | — | — | — | 3 | 3 | 6 |
Show 104 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative complications | D011183 | — | — | 1 | — | 3 | 4 | ||
| Analgesia | D000698 | — | — | 2 | — | 1 | 3 | ||
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | 2 | — | 1 | 3 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | 1 | 2 | ||
| Kidney transplantation | D016030 | — | 1 | 1 | — | — | 2 | ||
| Drug-related side effects and adverse reactions | D064420 | T88.7 | 1 | — | 1 | — | — | 2 | |
| Intratracheal intubation | D007442 | — | — | 1 | — | 1 | 2 | ||
| Aortic valve insufficiency | D001022 | EFO_0007148 | 1 | — | 1 | — | — | 2 | |
| Mitral valve insufficiency | D008944 | HP_0001653 | 1 | — | 1 | — | — | 2 | |
| Esophageal neoplasms | D004938 | C15 | — | — | 1 | — | — | 1 |
Show 20 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inguinal hernia | D006552 | HP_0000023 | K40 | — | 1 | — | — | 2 | 3 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | — | — | 2 | 3 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 1 | — | — | 2 | 3 |
| Phimosis | D010688 | EFO_1001104 | N47.1 | 1 | 1 | — | — | — | 2 |
| Paraphimosis | D010263 | EFO_1001086 | N47.2 | 1 | 1 | — | — | — | 2 |
| Balanitis | D001446 | EFO_1000833 | N48.1 | 1 | 1 | — | — | — | 2 |
| Cryptorchidism | D003456 | EFO_0004562 | Q53.1 | — | 1 | — | — | 1 | 2 |
| Lung injury | D055370 | S27.30 | 1 | 1 | — | — | 1 | 2 | |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 1 | 1 | — | — | 1 | 2 |
| Radical mastectomy | D015409 | 1 | 1 | — | — | — | 1 |
Show 9 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammation | D007249 | 2 | — | — | — | 1 | 3 | ||
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inhalation anesthesia | D000769 | — | — | — | — | 4 | 4 | ||
| Urinary bladder neoplasms | D001749 | C67 | — | — | — | — | 3 | 3 | |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 3 | 3 |
| Cerebral palsy | D002547 | G80 | — | — | — | — | 2 | 2 | |
| Operative surgical procedures | D013514 | — | — | — | — | 2 | 2 | ||
| Mitochondrial diseases | D028361 | EFO_0000591 | — | — | — | — | 2 | 2 | |
| Hemiarthroplasty | D062785 | — | — | — | — | 2 | 2 | ||
| Biliary atresia | D001656 | EFO_0004217 | Q44.2 | — | — | — | — | 2 | 2 |
| Rhytidoplasty | D015361 | — | — | — | — | 1 | 1 | ||
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | — | — | 1 | 1 |
Show 82 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SINECATECHINS |
| INN | — |
| Description | Sinecatechins (USAN, trade names Veregen and Polyphenon E) is a specific water extract of green tea leaves from Camellia sinensis that is the active ingredient in an ointment approved by the FDA in 2006 as a botanical drug to treat genital warts. Sinecatechins are mostly catechins, 55% of which is epigallocatechin gallate. It was the first botanical drug approved by the US FDA.
|
| Classification | Unknown |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201723 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 230 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,428 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more